CA2844907A1 - Concentrated felbamate formulations for parenteral administration - Google Patents

Concentrated felbamate formulations for parenteral administration Download PDF

Info

Publication number
CA2844907A1
CA2844907A1 CA2844907A CA2844907A CA2844907A1 CA 2844907 A1 CA2844907 A1 CA 2844907A1 CA 2844907 A CA2844907 A CA 2844907A CA 2844907 A CA2844907 A CA 2844907A CA 2844907 A1 CA2844907 A1 CA 2844907A1
Authority
CA
Canada
Prior art keywords
agent
microparticles
composition
weight
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2844907A
Other languages
English (en)
French (fr)
Inventor
Sasha H. Bakhru
Bryan E. Laulicht
Edith Mathiowitz
Solomon S. Steiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perosphere Pharmaceuticals Inc
Original Assignee
Perosphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perosphere Inc filed Critical Perosphere Inc
Publication of CA2844907A1 publication Critical patent/CA2844907A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2844907A 2011-08-12 2012-08-09 Concentrated felbamate formulations for parenteral administration Abandoned CA2844907A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161522811P 2011-08-12 2011-08-12
US61/522,811 2011-08-12
PCT/US2012/050148 WO2013025442A2 (en) 2011-08-12 2012-08-09 Concentrated felbamate formulations for parenteral administration

Publications (1)

Publication Number Publication Date
CA2844907A1 true CA2844907A1 (en) 2013-02-21

Family

ID=47715640

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2844907A Abandoned CA2844907A1 (en) 2011-08-12 2012-08-09 Concentrated felbamate formulations for parenteral administration

Country Status (7)

Country Link
US (2) US20140178479A1 (OSRAM)
EP (1) EP2741751A4 (OSRAM)
JP (3) JP2014525402A (OSRAM)
AU (1) AU2012295390B2 (OSRAM)
CA (1) CA2844907A1 (OSRAM)
HK (1) HK1198942A1 (OSRAM)
WO (1) WO2013025442A2 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3202898T3 (en) 2009-11-02 2019-01-14 Univ Washington THERAPEUTIC NUCLEASE COMPOSITIONS AND PROCEDURES
PH12013502441B1 (en) 2011-04-29 2019-02-08 Univ Washington Therapeutic nuclease compositions and methods
SI3063275T1 (sl) 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Terapevtske fuzije nukleaza-albumin in postopki
WO2015100252A1 (en) * 2013-12-23 2015-07-02 Perosphere, Inc. Deuterated felbamate, compositions containing the same, and methods of use thereof
GB201604359D0 (en) * 2016-03-15 2016-04-27 Univ Newcastle Treatment of tissue disorders
AU2017290389B2 (en) 2016-07-01 2024-09-26 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
US10947295B2 (en) 2017-08-22 2021-03-16 Sanabio, Llc Heterodimers of soluble interferon receptors and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1904257A (en) * 1926-10-29 1933-04-18 Firm Of Chemical Works Formerl Supersaturated calcium gluconate solution
US3017323A (en) * 1957-07-02 1962-01-16 Pfizer & Co C Therapeutic compositions comprising polyhydric alcohol solutions of tetracycline-type antibiotics
US5308621A (en) * 1991-02-18 1994-05-03 Commonwealth Scientific And Industrial Research Organisation Ascorbic acid composition and transdermal administration method
US6020367A (en) * 1997-12-02 2000-02-01 Avon Products, Inc. Supersaturated ascorbic acid solutions
ATE244564T1 (de) * 1999-02-09 2003-07-15 Univ Virginia Felbamat-derivate
ES2303527T3 (es) * 2000-05-10 2008-08-16 Jagotec Ag Procedimiento de molienda.
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
MXPA04009968A (es) * 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
US7259153B2 (en) * 2003-02-03 2007-08-21 Supernus Pharmaceuticals Drug formulation and delivery using crystalline methylated cyclodextrins
CN1791386A (zh) * 2003-05-19 2006-06-21 巴克斯特国际公司 抗癫痫和抗痴呆药物以及免疫抑制剂的小－颗粒药物制剂
US20060160776A1 (en) * 2003-05-28 2006-07-20 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
CN101309691A (zh) * 2005-09-30 2008-11-19 奥瓦什医药品公司 新的胃肠外的卡马西平制剂
CA2637359A1 (en) * 2006-01-17 2007-07-26 The Regents Of The University Of Colorado Central administration of stable formulations of therapeutic agents for cns conditions
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
US20120053220A1 (en) * 2007-08-02 2012-03-01 The General Hospital Corporation D/B/A Massachusetts General Hospital Novel lipoxygenase inhibitors as neuroprotective agents
EP2273993A4 (en) * 2008-04-01 2011-06-15 Univ Colorado Regents METHOD AND COMPOSITIONS FOR THE INTRA-CEREBRUCTIVE ADMINISTRATION OF FELBAMATE
US8637569B2 (en) * 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
CN103635179B (zh) * 2011-04-28 2017-12-29 普拉福姆五金器具第二有限公司 亲脂性药剂的改进的胃肠外制剂以及制备和使用其的方法

Also Published As

Publication number Publication date
US20170157083A1 (en) 2017-06-08
JP2019085416A (ja) 2019-06-06
HK1198942A1 (en) 2015-06-19
US20140178479A1 (en) 2014-06-26
JP2017122127A (ja) 2017-07-13
EP2741751A2 (en) 2014-06-18
WO2013025442A2 (en) 2013-02-21
AU2012295390B2 (en) 2015-12-24
WO2013025442A3 (en) 2013-04-25
EP2741751A4 (en) 2015-03-25
AU2012295390A1 (en) 2014-03-13
JP2014525402A (ja) 2014-09-29

Similar Documents

Publication Publication Date Title
US20170157083A1 (en) Concentrated felbamate formulations for parenteral administration
US20100062066A1 (en) Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
US12539274B2 (en) Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
US5653998A (en) Injectable liposomal pharmaceutical preparations
US8299124B2 (en) Aqueous intraocular penetration-promoting eye drop
JP2002539257A (ja) 薬剤の脳内生物学的利用率の増加
CN109715151A (zh) 用于治疗癫痫性紊乱的方法和组合物
PT100850B (pt) Composicoes farmaceuticas contendo uma mistura sinergica de um agente uricosurico, em especial,de probenecid, com um agente antagonista de aminoacidos excitantes, em especial,um derivado de quinoxalina substituido e sua utilizacao no tratamento de doencas neurodegenerativas
JP2009541484A (ja) ５ｈｔ６モジュレーターおよびコリンエステラーゼインヒビターを含む組み合わせ
CN107708686A (zh) 氧杂二环庚烷前药
WO2000037050A1 (en) Water-insoluble drug delivery system
CA2911837C (en) Stable pharmaceutical composition of clopidogrel free base for oral and parenteral delivery
JP6934581B2 (ja) エピナスチン又はその塩を含有する水性医薬組成物
BRPI0615349A2 (pt) composição farmacêutica compreendendo um quelador de ferro
JP4880449B2 (ja) ダントロレンを用いる治療
MX2008010394A (es) Tratamientos antivirales intravenosos.
AU2006254675A1 (en) Formulation comprising farnesyl dibenzodiazepinone and a pharmaceutically acceptable surfactant
JPH06263636A (ja) 脳または高次神経疾患治療剤
CN115103675B (zh) 用于治疗和预防中枢神经系统疾病的化合物
DE69919995T2 (de) Verwendung von cysteinprotease inhibitoren zur herstellung eines arzneimittels zur vorgbeugung und behandlung von gehirngewebezerrütung infolge hypertensive enzephalopathie oder encephalothlipsis
HK1047704A1 (en) New use of a macrolide compound
WO2015100252A1 (en) Deuterated felbamate, compositions containing the same, and methods of use thereof
HK1087919A (en) Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170804

FZDE Discontinued

Effective date: 20190809